The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC(NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.

The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC(NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.

MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.

MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-γ-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses thereof.

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.

The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.

The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.

Among the various aspects of the present disclosure is the provision of methods, synthetic DC, and compositions for T cell activation. The present disclosure provides for synthetic dendritic cells (DCs), methods of generating synthetic dendritic cells (DCs), methods of generating T cell-encapsulated gelatin microspheres and microcapsules, methods of activating T cells using synthetic DCs, methods for expanding T cells against individualized antigen-specific mutational antigens using synthetic DCs, and methods of treating a chronic disease (e.g., HIV, HPV) or cancer using the synthetic DCs.

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.